OakChart

Beta Bionics Inc

BBNXHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 3:59 PM ET

17.81+1.29 (7.81%)
2026-11-12 05:37 CET
Market cap
968.28 USD m
Revenue, TTM
127.27 USD m
Net income, TTM
-83.12 USD m
Free cash flow, TTM
-65.96 USD m
EPS diluted, TTM
-1.85
P/E
-
Compare

Price

BBNX against its 20, 50 and 200-day averages
2050200beat
10.0015.0020.003.6M7.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BBNXclose 17.8120-day 17.4850-day 18.60200-day 14.8017.8152w low

45.6% under the 52-week high of 32.71 on 26 Nov 2025. 52-week low 8.80 on 10 Apr 2026. Last 15 sessions, 55.0% high to low

Volume 0.75× normal · the line is the 50-bar volume average

Profile

BBNX
52-week range, 38% of the way up
8.8032.71

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

IndexRUT
Employees423
IPOJan 30, 2025
Beta3.41
ATR, 14d1.50
Rel volume0.75
Short float10.64%
Insider own13.93%
Inst own97.76%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap968.27M
Enterprise Value734.07M
Income-83.12M
Sales127.27M
Book/sh7.38
Cash/sh4.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees423
IPOJan 30, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S7.61
P/B2.41
P/C4.03
P/FCF-
EV/EBITDA-
EV/Sales5.77
Quick Ratio8.22
Current Ratio8.92
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.85
EPS next Y-2.13
EPS next Q-0.50
EPS this Y-12.96%
EPS next Y-3.99%
EPS next 5Y4.23%
EPS past 3/5Y-6.13% -
Sales past 3/5Y724.29% -
EPS Y/Y TTM-3.00%
Sales Y/Y TTM43.69%
EPS Q/Q-60.69%
Sales Q/Q30.28%
EarningsOct 27 AMC
EPS/Sales Surpr.0.63% 2.26%

Ownership

Insider Own13.93%
Insider Trans-2.36%
Inst Own97.76%
Inst Trans13.14%
ROA-21.48%
ROE-23.88%
ROIC-20.47%
Gross Margin58.63%
Oper. Margin-72.75%
Profit Margin-65.31%
SMA201.88%
SMA50-4.24%
SMA20020.34%
Trades-

Technical

Shs Outstand54.36M
Shs Float46.79M
Short Float10.64%
Short Ratio4.09
Short Interest4.98M
52W High32.71 -45.55%
52W Low8.80 102.39%
Volatility10.40% 8.72%
ATR (14)1.50
RSI (14)50.96
Beta3.41
Rel Volume0.75
Avg Volume1.22M
Volume909,447

Performance

Perf Week5.07%
Perf Month0.68%
Perf Quarter-1.49%
Perf Half Y84.94%
Perf YTD-41.55%
Perf Year-38.20%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.60
Target Price25.10
Prev Close16.52
Price17.81
Change %7.81%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedJJefferiesBuy$30+68.4%
Oct 07, 2026InitiatedBBarclaysOverweight$30+68.4%
Sep 23, 2026InitiatedWWells FargoOverweight$28+57.2%
Aug 21, 2026InitiatedWWilliam BlairMkt Perform
Jul 28, 2026ResumedUUBSBuy$22+23.5%
Feb 09, 2026InitiatedUUBSBuy$24+34.8%
Jan 27, 2026InitiatedTTD CowenHold$17-4.5%
Jan 09, 2026DowngradeBBofA SecuritiesBuy → Neutral
Oct 21, 2025ResumedSStifelBuy$26+46.0%
Oct 01, 2025UpgradeGGoldmanNeutral → Buy$26+46.0%

Peers

Mkt cap
TickerCompanyMkt cap
TNDMTandem Diabetes Care Inc1.31B
PODDInsulet Corp10.41B
DXCMDexcom Inc29.96B
MMEDMiniMed Group Inc5.13B
ABTAbbott Laboratories189.28B
SENSSenseonics Holdings Inc570.81M
AHCOAdaptHealth Corp1.06B
EMBCEmbecta Corp369.99M
MDTMedtronic Plc129.98B
ICUIICU Medical Inc4.46B

Insider trading

latest 14 of 88
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Stephen FeiderOfficerNov 09 '26Proposed Sale17.0074412,649Nov 09 04:52 PM
Feider StephenChief Financial OfficerNov 05 '26Option Exercise5.103821,948159,760Nov 09 04:26 PM
Feider StephenChief Financial OfficerNov 05 '26Sale17.043826,508159,378Nov 09 04:26 PM
Stephen FeiderOfficerNov 05 '26Proposed Sale17.043826,508Nov 05 04:06 PM
Hopman MarkChief Commercial OfficerNov 02 '26Sale16.903706,25354,143Nov 04 04:08 PM
Mensinger MikeChief Product OfficerOct 27 '26Sale22.002,65058,300174,740Oct 29 04:22 PM
Hopman MarkChief Commercial OfficerOct 26 '26Sale20.0082116,42054,513Oct 28 04:03 PM
Hopman MarkChief Commercial OfficerOct 14 '26Sale17.3577513,44655,334Oct 16 04:10 PM
Hopman MarkChief Commercial OfficerOct 01 '26Sale18.963707,01556,109Oct 05 05:11 PM
MARK HOPMANOfficerOct 01 '26Proposed Sale18.982,66050,487Oct 01 04:30 PM
Jones ChristyDirectorSep 22 '26Sale23.006,430147,89019,564Sep 23 05:40 PM
CHRISTINA JONESDirectorSep 22 '26Proposed Sale22.048,942197,082Sep 22 04:15 PM
Hopman MarkChief Commercial OfficerSep 16 '26Sale20.1330,779619,64056,479Sep 17 04:15 PM
Mensinger MikeChief Product OfficerSep 16 '26Sale22.002,65058,300177,390Sep 17 04:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
TMSLT. Rowe Price Small-Mid Cap ETFAUM: 3.28B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHIiShares U.S. Medical Devices ETFAUM: 4.07B
XHEState Street SPDR S&P Health Care Equipment ETFAUM: 160.14M
PTHInvesco Dorsey Wright Healthcare Momentum ETFAUM: 291.00M

News

latest 14 of 188

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-27-0.520-0.523-0.52135.5134.7214
2026Q22026-07-29-0.530-0.581-0.52532.0131.4610
2026Q12026-04-21-0.490-0.503-0.49327.6326.9511
2025Q42026-02-17-0.300-0.403-0.30532.1230.3912
2025Q32025-10-28-0.330-0.423-0.32627.2523.9710
2025Q22025-07-29-0.390-0.459-0.38823.2419.699
2025Q12025-05-06-0.930-0.476-0.66117.6416.157
2024Q42025-03-25-2.720-0.900-0.41820.4420.195
2024Q32024-11-27-0.755--0.22716.70--
2026Q4---0.502--30.4214
2027Q1---0.527--35.2511
2027Q2---0.534--41.0811
2027Q3---0.549--49.4211
2027Q4---0.541--57.8010
2028Q1---0.465--61.982
2028Q2---0.430--68.552

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-8.600-2.133-1.26365.1264.87
2025FY-1.810-1.965-1.807100.2598.58
2026FY--2.045--125.54
2027FY--2.126--184.65
2028FY--1.590--284.54
2029FY--1.430--369.98
2030FY--0.640--478.77

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-30146830.4228.7932.30
2026Q4S2026-10-28146731.1429.3038.86
2026Q4S2026-10-27140932.2828.0039.60
2026Q4S2026-10-13140932.2828.0039.60
2026Q4S2026-10-081401032.2828.0039.60
2026Q4S2026-09-221301032.2228.0039.60
2026Q4S2026-09-151201032.4628.0039.60
2026Q4S2026-09-141201032.4628.0039.60
2026Q4S2026-09-111201033.3128.0039.60
2026Q4S2026-09-10121539.1638.0040.55
2026Q4S2026-08-20121539.1638.0040.65
2026Q4S2026-08-19121539.1638.0040.65
2026Q4S2026-07-30111539.1238.0040.65
2026Q4S2026-07-27111039.3738.5040.55

Estimate history

EPS, annual-1.511-1.029-1.263-1.806-1.8461
Period2022202320242025TTM
EPS, quarterly-0.227-0.418-0.661-0.388-0.326-0.305-0.493-0.525-0.523
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.17911.99565.124100.251127.27
Period2022202320242025TTM
Sales, quarterly16.70520.4417.63923.23827.25332.12127.62632.01335.505
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual42.85942.85943.34944.36154.363
Period2022202320242025MRQ
Shares, quarterly42.85943.34943.35443.46543.99244.36144.56244.98254.363
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue127.27100.2565.1211.990.18
Cost of Goods Sold Incl. D&A52.6544.7129.245.692.09
Gross Profit74.6155.5435.896.31-1.91
Selling, General and Administrative Excl. Other167.20127.2281.1442.1663.94
Research and Development42.7034.7926.1817.9431.43
Other Operating Expense0.000.000.000.000.00
Operating Income-92.58-71.68-45.25-35.85-65.84
Interest Expense0.000.000.000.000.00
Unusual Expense0.0012.4513.419.96-0.91
Net Income Before Taxes-83.12-73.20-54.76-44.10-64.75
Income Taxes0.000.000.000.000.00
Consolidated Net Income-83.12-73.20-54.76-44.10-64.75
Net Income From Continuing Operations-83.12-73.20-54.76-44.10-64.75
Net Income-83.12-73.20-54.76-44.10-64.75
EPS (Recurring)-1.79-1.59-1.05-0.87-1.53
EPS (Basic, Before Extraordinaries)-1.85-1.81-1.26-1.03-1.51
EPS (Diluted)-1.85-1.81-1.26-1.03-1.51
EBITDA-88.63-68.81-42.97-33.76-63.76
Non-Operating Income (Expense)9.4610.933.911.710.18
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense23.4416.386.385.666.10
Price To Sales Ratio6.9412.32---
Gross Margin58.6355.4055.1152.59-1,065.92
Operating Margin-72.75-71.50-69.48-298.87-36,784.36
Net Margin-65.31-73.02-84.08-367.64-36,173.74
Shares Outstanding54.3644.3643.3542.8642.86
Market Capitalization968.28968.281,407.47--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue35.5132.0127.6332.1227.2523.2417.6420.44
Cost of Goods Sold Incl. D&A15.1713.1111.1913.1812.1310.738.678.75
Gross Profit20.3318.9016.4418.9415.1212.508.9711.69
Selling, General and Administrative Excl. Other46.9444.4840.7135.0732.1632.3827.6124.73
Research and Development11.9710.2410.3610.138.208.877.599.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-26.61-25.58-24.27-16.12-17.04-19.87-18.64-13.04
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.0012.456.02
Net Income Before Taxes-24.35-23.40-21.89-13.47-14.21-16.87-28.66-18.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-24.35-23.40-21.89-13.47-14.21-16.87-28.66-18.11
Net Income From Continuing Operations-24.35-23.40-21.89-13.47-14.21-16.87-28.66-18.11
Net Income-24.35-23.40-21.89-13.47-14.21-16.87-28.66-18.11
EPS (Recurring)-0.52-0.53-0.49-0.30-0.33-0.39-0.46-0.32
EPS (Basic, Before Extraordinaries)-0.52-0.53-0.49-0.30-0.33-0.39-0.66-0.42
EPS (Diluted)-0.52-0.53-0.49-0.30-0.33-0.39-0.66-0.42
EBITDA-25.30-24.46-23.28-15.59-16.36-19.22-18.04-12.51
Non-Operating Income (Expense)2.262.172.382.662.833.002.440.95
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.717.025.414.304.484.802.801.55
Price To Sales Ratio6.945.874.0413.439.798.117.60-
Gross Margin57.2659.0459.5058.9855.4853.8050.8657.19
Operating Margin-74.94-79.90-87.86-50.20-62.54-85.52-105.69-63.78
Net Margin-68.59-73.10-79.26-41.92-52.14-72.59-162.46-88.59
Shares Outstanding54.3644.9844.5644.3643.9943.4743.3543.35
Market Capitalization968.28698.28444.711,341.43863.75631.27530.59507.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments219.22103.5896.7527.68
Short Term Receivables19.6312.004.450.00
Inventories21.7213.321.250.00
Other Current Assets7.334.031.180.79
Total Current Assets267.90132.92103.6228.47
Net Property, Plant & Equipment15.2311.426.206.87
Total Investments and Advances45.430.100.100.10
Other Assets0.185.200.120.09
Total Assets328.74149.65110.0435.53
Short Term Debt Incl. Current Port. of LT Debt1.941.531.220.98
Accounts Payable5.002.851.170.43
Other Current Liabilities23.9916.778.217.47
Total Current Liabilities30.9221.1510.618.87
Long Term Debt5.375.733.003.16
Provision for Risks Charges0.000.000.000.00
Other Liabilities4.8446.7637.8310.50
Total Liabilities41.1373.6351.4322.53
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.00321.37261.71183.03
Common Equity287.61-245.36-203.10-170.03
Total Shareholders Equity287.6176.0158.6113.00
Accumulated Minority Interest0.000.000.000.00
Total Equity287.6176.0158.6113.00
Total Liabilities & Stockholders Equity328.74149.65110.0435.53
Book Value Per Share6.48-5.66-4.74-3.97
Tangible Book Value Per Share6.48-5.66-4.74-3.97
Full-Time Employees423291277-
Price to Book Ratio2.414.77--
Return on Assets-30.60-42.17-60.59-
Return on Equity-40.26-81.35-123.17-
Return on Invested Capital-24.99-66.99-71.58-400.76
Quick Ratio7.965.669.653.21
Current Ratio8.666.299.773.21

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-83.12-73.20-54.76-44.10-64.75
Depreciation4.352.882.282.092.09
Other Funds (Non Cash)24.1828.3916.3514.875.25
Funds from Operations-54.59-41.93-36.12-27.14-57.42
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-4.78-8.99-12.15-5.30-2.79
Cash from Operating Activities-59.37-50.92-48.27-32.45-60.21
Capital Expenditures-6.59-5.30-3.40-0.40-0.77
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.050.000.00
Purchase or Sale of Investments-58.06-157.51-0.13-69.300.00
Purchase of Investments-248.06-327.51-72.13-69.300.00
Sale Or Maturity of Investments190.00170.0072.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-64.65-162.81-3.48-69.69-0.77
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock167.08214.8755.62101.0356.78
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock167.08214.8755.62101.0356.78
Proceedsfrom Stock Options160.90210.1255.51101.0056.39
Issuance or Reduction of Debt, Net0.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities167.08214.8755.62101.0356.78
Net Change in Cash43.071.143.87-1.11-4.20
Free Cash Flow-65.96-56.22-51.67-32.85-60.98
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments240.30180.59199.62219.22228.69249.72
Short Term Receivables23.4519.9617.8919.6314.2513.43
Inventories22.9723.9223.7321.7220.3717.32
Other Current Assets6.226.576.757.336.715.60
Total Current Assets292.95231.03247.99267.90270.03286.07
Net Property, Plant & Equipment17.1616.5616.3915.2314.4112.50
Total Investments and Advances133.4444.6539.8745.4345.4331.25
Other Assets0.210.140.180.180.180.14
Total Assets443.76292.39304.42328.74330.05329.97
Short Term Debt Incl. Current Port. of LT Debt1.451.591.841.941.981.52
Accounts Payable4.685.352.325.004.463.42
Other Current Liabilities26.7019.0719.0323.9918.9514.55
Total Current Liabilities32.8426.0223.1930.9225.3919.49
Long Term Debt4.654.925.075.375.715.17
Provision for Risks Charges1.411.630.000.000.000.00
Other Liabilities3.483.454.914.844.193.68
Total Liabilities42.3836.0233.1741.1335.2928.34
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity401.38256.37271.25287.61294.76301.63
Total Shareholders Equity401.38256.37271.25287.61294.76301.63
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity401.38256.37271.25287.61294.76301.63
Total Liabilities & Stockholders Equity443.76292.39304.42328.74330.05329.97
Book Value Per Share7.385.706.096.486.706.94
Tangible Book Value Per Share7.385.706.096.486.706.94
Full-Time Employees---423409-
Price to Book Ratio2.412.571.554.552.862.01
Return on Assets-21.48-23.45-20.68-30.60-36.46-
Return on Equity-23.88-26.16-22.71-40.26-47.52-
Return on Invested Capital-6.00-8.96-7.92-4.60-4.73-5.50
Quick Ratio8.227.969.677.969.8313.79
Current Ratio8.928.8810.698.6610.6414.68

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-24.35-23.40-21.89-13.47-14.21-16.87
Depreciation1.311.120.990.940.680.65
Other Funds (Non Cash)6.507.155.295.244.484.12
Funds from Operations-16.55-15.13-15.62-7.29-9.05-12.10
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.260.51-8.21-1.340.32-1.50
Cash from Operating Activities-12.29-14.62-23.83-8.63-8.73-13.59
Capital Expenditures-2.27-1.04-1.38-1.90-1.28-1.78
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-111.8127.9723.222.5610.777.95
Purchase of Investments-157.81-20.03-24.78-45.44-60.23-15.05
Sale Or Maturity of Investments46.0048.0048.0048.0071.0023.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-114.0826.9321.840.669.496.17
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock163.601.800.621.062.650.04
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock163.601.800.621.062.650.04
Proceedsfrom Stock Options161.800.000.00-0.900.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities163.601.800.621.062.650.04
Net Change in Cash37.2314.11-1.37-6.913.41-7.38
Free Cash Flow-14.56-15.66-25.21-10.53-10.01-15.37

Revenue breakdown

Single Use Products2024: 16.41M 2025: 47.50M
iLet2024: 48.72M 2025: 52.75M
United States2024: 65.12M 2025: 100.25M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.64%5.0M46.8M1.29M
2026-10-1514.90%6.9M46.4M1.28M
2026-09-3013.45%6.0M44.9M1.29M
2026-09-1523.63%10.6M44.9M1.16M
2026-08-3125.14%9.4M37.4M1.15M
2026-08-1422.17%7.5M33.8M1.11M
2026-07-3122.57%7.6M33.7M981.02K
2026-07-1519.80%6.6M33.4M963.77K
2026-06-3020.45%6.8M33.4M1.00M
2026-06-1514.24%4.7M32.8M991.67K
2026-05-2915.58%5.2M33.4M1.00M
2026-05-1517.00%5.7M33.5M1.10M
2026-04-3018.24%6.2M34.0M1.18M
2026-04-1521.03%7.1M33.9M1.15M
2026-03-3122.01%7.6M34.5M1.30M
2026-03-1320.29%7.0M34.5M1.29M
2026-02-2716.30%5.6M34.5M1.24M
2026-02-1316.67%5.8M34.5M1.10M
2026-01-3016.40%5.5M33.4M1.02M
2026-01-1516.62%5.6M33.4M1.00M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call7.508.2012.200.008.0550.000.000.985-0.0180.001
call10.005.709.600.005.7740.000.000.978-0.0170.001
call12.503.207.100.004.2350.000.000.967-0.0160.002
call15.000.754.703.603.06711.000.000.727-0.2520.009
call17.500.002.750.552.37220.000.000.611-0.1890.011
call20.000.003.501.743.22228.000.000.508-0.2020.011
call22.500.003.400.413.85020.000.000.464-0.2410.011
call25.000.003.404.204.3565.000.000.436-0.2700.011
call30.000.003.401.415.14714.000.000.401-0.3130.011
call35.000.003.400.405.7553.000.000.380-0.3440.011
put7.500.003.400.052.8664.000.00-0.015-0.0170.001
put10.000.003.400.001.9960.000.00-0.022-0.0160.001
put12.500.000.050.006.1720.000.00-0.203-0.2640.008
put15.000.003.500.004.8190.000.00-0.273-0.2500.009
put17.500.003.701.253.66613.000.00-0.389-0.1880.011
put20.000.954.604.922.9326.000.00-0.492-0.2000.011
put22.503.306.800.003.2850.000.00-0.536-0.2380.011
put25.005.809.300.003.7850.000.00-0.564-0.2670.011
put30.0010.8014.300.004.5660.000.00-0.599-0.3090.011
put35.0015.8019.300.005.1680.000.00-0.620-0.3400.011

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-09SCHEDULE 13G/ASEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-2710-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-07SCHEDULE 13GSEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-184/A2026-09-09SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-178-KCurrent report2026-09-15SEC
2026-09-17424B5SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-09-16424B5SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-158-KCurrent report2026-09-14SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110012.76K2
2026-100095.18K4
2026-09002.35M11
2026-080000
2026-070000
2026-0600725.57K11
2026-050041.02K3
2026-040000
2026-030099.71K6
2026-020000
2026-0100887.85K3
2025-1200370.68K8
2025-110000

Institutional holders

Manager% owned
EVENTIDE ASSET MANAGEMENT, LLC14.03%
Soleus Capital Management, L.P.9.86%
MORGAN STANLEY9.58%
Sands Capital Alternatives, LLC8.32%
BlackRock, Inc.7.50%
Point72 Asset Management, L.P.5.06%
VANGUARD CAPITAL MANAGEMENT LLC4.00%
Vestal Point Capital, LP3.59%
RTW INVESTMENTS, LP3.37%
DEERFIELD MANAGEMENT COMPANY, L.P.2.97%

Funds

Fund% owned
Eventide Gilead Fund8.94%
Eventide Healthcare & Life Sciences Fund4.61%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
iShares Russell 2000 ETF2.38%
BRUCE FUND1.49%
VANGUARD EXTENDED MARKET INDEX FUND1.05%
Fidelity Small Cap Index Fund0.99%
iShares Russell 2000 Value ETF0.85%
VANGUARD RUSSELL 2000 INDEX FUND0.52%
JPMorgan Small Cap Value Fund0.50%

OakChart. BBNX. Cached 15 minutes.